Other publications - Rare Cancers Genomics

OTHER RARE CANCER GENOMICS PUBLICATIONS

 

TERT expression defines clinical outcome in pulmonary carcinoids. Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Lupo AM, Pelosi G, Absenger G, Altmüller J, Berthet JP, Bibeau F, Blanc Fourner C, Boland A, Bonnetaud C, Brcic L, Brevet M, Brustugun OT, Centonze G, Chalabreysse L, Cohen C, Deleuze JF, Derks JL, Di Micco CM, Dingemans AMC, Fadel E, Graziano P, Hofman P, Hofman V, Lacomme S, Lund-Iversen M, Metovic J, Milione M, Moonen L, Muscarella LA, Nürnberg P, Olaso R, Meyer V, Papotti M, Perrin C, Planchard G, Popper H, Rousseau N, Roz L, Sabella G, SparaneoA, Speel EJM, Thivolet-Béjui F, Thomas de Montpréville V, Vignaud JM, Volante M, Wright GM, Damiola F, Tabone-Eglinger S, Girard N, George J, Bosco G, Quaas A, Tang LH, Robzyk K, Kadota K, Roh MS, Fanaroff RE, Falcon CJ, Büttner R, Lantuejoul S, Rekhtman N, Rudin C, Travis WD, Alcala N, Fernandez-Cuesta L, Foll M, Peifer M, Thomas RK, Fischer, M. JCO. Accepted.

Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery. Blázquez-Encinas R, García-Vioque V, Caro-Cuenca T, Moreno-Montilla MT, Mangili F, Alors-Pérez E, Ventura S, Herrera-Martínez AD, Moreno-Casado P, Calzado MA, Salvatierra A, Gálvez-Moreno MA, Fernandez-Cuesta L, Foll M, Luque RM, Alcala N, Pedraza-Arevalo S, Ibáñez-Costa A, Castaño JP. J Transl Med. 2023.

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancersMc Leer A, Foll M, Brevet M, Antoine M, Novello S, Mondet J, Cadranel J, Girard N, Giaj Levra M, Demontrond P, Audigier-Valette C, Letouzé E, Lantuéjoul S, Fernandez-Cuesta L, Moro-Sibilot D. Lung Cancer. 2022. PMID: 35183375

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from MESOPATH Référence Center. Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, Brcic L, Capron F, Chirieac LR, Damiola F, Sequeiros R, Cazes A, Damotte D, Foulet A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Paindavoine S, Picquenot JM, Rouquette I, Sagan C, Sauter J, Thivolet F, Brevet M, Rouvier P, Travis WD, Planchard G, Weynand B, Clozel T, Wainrib G, Fernandez-Cuesta L, Pairon JC, Rusch V, Girard N. 
J Thorac Oncol. 2020. PMID: 32165206